HOTH THERAPEUTICS
​Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
HOTH THERAPEUTICS
Industry:
Biotechnology Health Care Hospital Medical
Founded:
2017-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.hoththerapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
32.68 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Mobile Non Scaleable Content Sitelinks Search Box Organization Schema IPv6
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Newest Events participated
Official Site Inspections
http://www.hoththerapeutics.com
- Host name: 86.119.72.148.host.secureserver.net
- IP address: 148.72.119.86
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Hoth Therapeutics"
Home - Hoth Therapeutics
[email protected]. About Hoth Therapeutics. At Hoth Therapeutics, we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of …See details»
Overview - Hoth Therapeutics, Inc.
Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors. Shareholders and interested parties may …See details»
Board of directors - Hoth Therapeutics, Inc.
Wayne D. Linsley has served as a director of the Company since April 2020. Mr. Linsley has been in business management for over 40 years. He possesses a wide and varied skillset including …See details»
Hoth Therapeutics - Crunchbase Company Profile
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. …See details»
Hoth Therapeutics, Inc | LinkedIn
Hoth Therapeutics, Inc | 1,186 followers on LinkedIn. Patient Focused Treatment Solutions for Unmet Medical Needs | At Hoth Therapeutics, Inc. (NASDAQ: HOTH), we strive to develop …See details»
Hoth Therapeutics, Inc. (HOTH) - Yahoo Finance Canada
Aug 7, 2019 Description . Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical …See details»
Frequently Asked Questions - Hoth Therapeutics, Inc.
Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors. Shareholders and interested parties may …See details»
Our Team - Hoth Therapeutics
[email protected]. About Hoth Therapeutics. At Hoth Therapeutics, we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient …See details»
Hoth Therapeutics (HOTH) Company Profile & Description - Stock …
Feb 15, 2019 Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in …See details»
Hoth Therapeutics Announces Plans to Submit Expanded Access …
Mar 10, 2025 For more information about HT-001, ongoing clinical trials, or the Expanded Access Program, please visit www.hoththerapeutics.com . About Hoth Therapeutics, Inc.See details»
Presentation - Hoth Therapeutics, Inc.
Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors. Shareholders and interested parties may …See details»
For Patients - Hoth Therapeutics
[email protected]. About Hoth Therapeutics. At Hoth Therapeutics, we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of …See details»
Hoth Therapeutics Announces Update on Cancer Therapeutic HT …
Oct 29, 2024 www.hoththerapeutics.com Phone: (678) 570-6791. SOURCE Hoth Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ …See details»
Hoth Therapeutics Enters Partnership with the Department of …
Dec 26, 2024 Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001. NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: …See details»
Hoth Therapeutics announces ‘positive’ results from study of HT-KIT
5 days ago Hoth Therapeutics announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors.The results …See details»
Contact us - Hoth Therapeutics
Hoth Therapeutics New York, NY. 1177 Avenue of the Americas 5th Floor New York, NY 10036See details»
Pipeline - Hoth Therapeutics
[email protected]. About Hoth Therapeutics. At Hoth Therapeutics, we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of …See details»
Hoth Therapeutics Announces Positive Preclinical Results for HT …
5 days ago Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the efficacy of HT …See details»
August 2023 Innovating for Everyone - ir.hoththerapeutics.com
HT-001: Value Proposition: HOTH Market Growth: EGFR Inhibitor Skin Toxicity market predicted to grow from $52M in 2018 to $391M by end of 2030* Mechanism of Action: 12-week study …See details»
Press Releases - Hoth Therapeutics, Inc.
Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors. Shareholders and interested parties may …See details»